Adalimumab, a fully human monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), is widely used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis (Gaggiano et al., 2025). This evidence concerns the gene TNF and Crohn disease.